Drug Safety-related Labeling Changes (SrLC)

Get Email Alerts | Guide

HIBISTAT (NDA-018300)

(CHLORHEXIDINE GLUCONATE)

Safety-related Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)

Download Data

04/19/2018 (SUPPL-19)

Approved Drug Label (PDF)

5 Warnings and Precautions

DRUG FACTS

WARNINGS

(additions underlined)

 

For external use only. Flammable: Keep away from fire or flame

Allergy alert:

This product may cause a severe allergic reaction. Symptoms may include:

  • wheezing/diffi ulty breathing

  • shock

  •  facial swelling

  •  hives

  •  rash

If an allergic reaction occurs, stop use and seek medical help right away.

Questions related to the drug data in these files should be directed to the Center for Drug Evaluation and Research, Division of Drug Information
druginfo@fda.hhs.gov.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English